Deepak Fertilisers: FY26 Results — The Story of Two Halves

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Deepak Fertilisers delivered revenue growth of 12% to ₹11,506 Cr in FY26, but the earnings story fractured in half. The first half rode commodity strength and subsidy tailwinds; the second half absorbed a perfect storm: ammonia plant shutdown, fertiliser input-cost shocks, inadequate subsidy pass-through, and global supply disruptions in IPA and mining chemicals. Net profit fell 22% to ₹739 Cr despite lower finance costs—a reminder that top-line growth masks underlying margin stress.

The company navigated structural headwinds with two massive capex projects (₹4,650 Cr total) now 95% and 86% complete, commissioning expected Q2 FY27. Management signals improving conditions ahead: tightening global supply, LNG contract first cargo arrived, and strategic mix upgrades. The balance sheet is stretched—net debt at ₹4,824 Cr, 2.86x EBITDA—but consistent with the final stage of a major investment cycle.

The core tension: revenue grew while profitability fell, and the company is about to add significant new capacity into a normalizing market. Does the capex-driven growth in FY27 justify today’s multiple, or is the market pricing for a reset?

2 — Introduction

Deepak Fertilisers operates across three chemistry verticals: mining explosives (Technical Ammonium Nitrate), industrial chemicals (nitric acid, isopropyl alcohol), and crop nutrition (NPK, specialty fertilisers). The company was incorporated in 1979 and is India’s only solid-TAN manufacturer and one of Asia’s largest nitric acid producers.

FY26 marked a year of contradictions. Management’s own language—”a story of two halves”—framed H1 as strong, H2 as materially weaker due to exogenous shocks. Revenue grew 12% YoY; EBITDA contracted 13%. The company received its first LNG cargo from a 15-year Equinor contract, a structural hedge against gas-cost volatility. Simultaneously, it completed an acquisition in explosives (Chardham Chemicals) to pursue vertical integration in mining solutions. The board recommended a 100% dividend (₹10 per share) despite net profit decline.

Two projects dominate the forward outlook: Gopalpur TAN (₹2,675 Cr capex, 376 KTPA capacity) and Dahej nitric acid (₹1,983 Cr capex, adding 300 KTPA WNA and 150 KTPA CNA). Both are 86–95% complete and expected to commission in Q2 FY27, bringing total capex deployed to ₹1,569 Cr in FY26 alone.

3 — Business Model: WTF Do They Even Do?

Deepak Fertilisers is a chemical conglomerate selling three product classes to wildly different customers. The business model works because the company has built scale, location advantage, and application-specific product depth in each vertical.

Mining Chemicals / TAN (26% of FY26 revenue, ₹2,604 Cr): The company sells Technical Ammonium Nitrate—a precursor to explosives—to mining companies, tunnel-boring contractors, and infrastructure projects. It is India’s only solid-TAN manufacturer and the only producer of high-density, low-density, and medical-grade variants. Plants sit on India’s east and west coasts, proximate to mining belts. The company now sells 16% of TAN direct to end-users (B2C), a strategic shift from the traditional B2B model to mining exploder companies. This mix upgrade improves realisations and customer lock-in.

Industrial Chemicals / Nitric Acid and IPA (18% of FY26 revenue, ₹1,842 Cr): The company is the largest nitric acid manufacturer in Asia and a major producer of isopropyl alcohol (IPA, a solvent for pharma, cosmetics, and electronics). It operates a 70 KTPA IPA plant and diluted/concentrated nitric acid plants totalling 885 and 231 KTPA respectively. Geographic advantage is stark: Dahej and Gujarat plants sit in the nitro-aromatic and chemical derivatives belt; Panipat serves northern India; Taloja serves Maharashtra. The company is exploring specialty grades—solar-grade nitric acid, pharmaceutical-grade IPA, and electronic-grade IPA—to move upstream into value-added verticals.

Crop Nutrition (50% of FY26 revenue, ₹6,166 Cr): This is the volume game—NPK, urea, and specialty fertilisers under the brands Smartek and Croptek. The company is not the largest, but it leads in specialty and water-soluble fertilisers (Bentonite Sulphur, for example). It enjoys scale on NPK (800 KTPA capacity) and access to the richest agricultural belts of Maharashtra and Karnataka. The leverage here is subsidy—the Indian government subsidizes fertiliser farmers; swings in subsidy lag cause margin compression even as costs spike. Specialties (33% of segment revenue in FY26) carry better premiums and insulate the business from commodity pricing wars.

The business model is defensible because each vertical has structural moats: TAN (only manufacturer), nitric acid (largest scale in Asia), and specialty fertilisers (brand and application depth). The trade-off is leverage to commodity cycles and government policy.

4 — Financials Overview

Figures are consolidated, in ₹ crore.

The earnings decline is a story of input-cost pass-through failure. Management disclosed that Q4 carried a planned ammonia shutdown impact of ₹70–75 Cr (about 10% of quarterly EBITDA). Adjusting this, underlying FY26 EBITDA would have been ₹1,759 Cr, still a -9% YoY decline. The core driver was margin compression in fertilisers—raw materials (phosphoric acid, sulphur, ammonia) spiked due to Russia-Ukraine disruptions and global tightness; Indian fertiliser subsidy policy held farmer prices of urea and DAP flat (elections), leaving companies unable to pass cost hikes to end-users or to claim full subsidy-bridge support.

PAT margin fell 276 bps despite a 59 bp benefit from lower finance costs (₹353 Cr in FY26 vs. ₹413 Cr in FY25). The decline was all margin compression—not a debt-servicing relief story.

From the Q4 FY26 earnings call (May 2026): Management flagged three exogenous disruptions—LPG/propylene shortages (hurting IPA), LNG vessel delays (hurting fertiliser/chemical segments), China export bans on critical products, and India’s ammonia nitrate export ban. On the LNG side, the Equinor contract’s first cargo arrived in May 2026 (post-quarter). Management expects this to provide cost visibility and stability once the contract begins flowing through reported results (likely Q1 FY27 onwards).

5 — Valuation Discussion: Fair Value Range (Educational Only)

What follows is a walkthrough of how three valuation methods work, using this company’s numbers as the example — not a target, not a forecast, not advice.

Method 1 (P/E on annualised FY26 EPS): FY26 reported EPS was ₹58.40 (net profit ₹739 Cr ÷ 12.6 Cr shares). The market pays 25.6x on this EPS at a referenced price of ₹1,494. Peer band (SRF, GNFC, GHCL, Tata Chemicals) trades at 8.99x to 67.03x; median is 20.51x. Applying the peer band: 58.40 × 8.99 to 20.51x produces ₹525 to ₹1,197.

Method 2 (EV/EBITDA): FY26 EBITDA was ₹1,684 Cr. Enterprise Value = Market Cap (₹18,861 Cr) + Net Debt (₹4,824 Cr) = ₹23,685 Cr. EV/EBITDA = 14.1x. Peer EV/EBITDA range is 3.42x (Tata Chemicals) to 23.66x (Tanfac); median is 8.48x. Applying median: 1,684 × 8.48 = ₹14,279 Cr EV. Subtracting net debt of ₹4,824 Cr gives implied market cap of ₹9,455 Cr, or ₹749 per share (using 12.6 Cr shares). Using the broader peer band (8.48x to 17.41x): 1,684 × 8.48 to 17.41x = ₹14,279 to ₹29,345 Cr EV; less net debt = ₹9,455 to ₹24,521 Cr market cap, or ₹749 to ₹1,946 per share.

Method 3 (Simplified DCF on reported cash flow): FY26 operating cash flow was ₹206 Cr; capital expenditure was ₹1,569 Cr, resulting in free cash flow of -₹1,386 Cr. The company is in capex-build mode. A normalized FCF assumption (post-capex wind-down in FY28) of ₹800 Cr, grown at 5% perpetually and discounted at 9% (cost of capital estimate), produces a terminal value of ₹800/(0.09-0.05) = ₹20,000 Cr. This is illustrative and does not account for the step-up in earnings once the two new projects commission.

These figures show how the methods work and are not a valuation, a target, or advice.

6 — What’s Cooking

Capex projects near completion: Gopalpur TAN (₹2,675 Cr, 376 KTPA) is 95% done; Dahej nitric acid (₹1,983 Cr, 300 WNA + 150 CNA KTPA) is 86% done. Both expect Q2 FY27 commissioning. Post-completion, the company will operate ~1.0 MMTPA TAN capacity (3rd largest pure-play globally) and ~1.2 MMTPA WNA capacity (Asia’s largest). CWIP stands at ₹3,046 Cr (March 2026).

LNG supply security: First Equinor cargo arrived May 2026 under a 15-year contract. Management framed this as both a physical hedge (supply surety in a tight ammonia market) and a financial one (cost visibility vs. spot-based sourcing). Benefits not yet visible in FY26 results; likely to flow through from Q1 FY27.

Explosives unit acquisition: DMSL (Deepak Mining Solutions, a subsidiary) completed acquisition of Chardham Chemicals (an explosives manufacturer) for ₹121.45 Cr cash in May 2026. Strategic intent: shift from pure TAN supplier to “holistic mining solutions provider” offering blasting services, cost-optimization advice, and integrated solutions. Valuation rationale was land, licenses, plant, and location proximity to market. Management said capex to upgrade is “not large” and deferred detailed financial guidance pending integration.

Subsidy lag and policy risk: Government subsidy on urea and DAP was held flat during elections (FY26 was an election year). This caused an unprecedented gap between cost inflation and subsidy reimbursement. The Fertiliser Industry has formally requested the government to recalibrate subsidy to cover war-led raw material hikes. Management flagged this as a “near-term” headwind but signaled confidence in eventual resolution.

El Niño and monsoon risk: IMD forecast below-normal monsoon (92% of long-period average) for 2026, linked to El Niño. Management is monitoring, but geographic exposure is mixed—irrigation-heavy regions (Maharashtra, Karnataka) may be less impacted than rainfed areas. Early granular data not yet available.

Acquisition integration timeline: Management deferred revenue and EBITDA guidance for the Chardham acquisition pending integration planning. A project team is being formed; detailed guidance to follow.

7 — Balance Sheet

The balance sheet is leveraged—a deliberate choice to fund capex. Total debt rose ₹1,553 Cr; net debt rose ₹1,519 Cr (cash inflows of ₹43+49 Cr partially offset the gross borrowing increase). The company raised ₹80 Cr in Compulsory Convertible Debentures (CCDs) issued to its subsidiary DMSL, and capex-related project borrowing of ₹1,039 Cr also lifted long-term debt.

Three sarcastic observations: (1) The company is burning cash operationally in the capex phase (FY26 operating cash was only ₹206 Cr against ₹1,569 Cr capex spend), which is why net debt ballooned 46% despite equity gains. (2) Short-term debt at ₹1,413 Cr is now material—1.3x FY26 PAT—suggesting working capital stress from elevated inventory and receivables. (3) Management has said capex will “revert to maintenance levels” after FY27, implying debt should stabilize once projects begin earning.

The equity base (₹7,464 Cr) holds steady at ~45% of total capital—reasonable for a capex-intensive business. But the leverage ratio of 2.86x EBITDA is at the upper bound of comfort for a cyclical industrial company.

8 — Cash Flow: Sab Number Game Hai

The money story is straightforward: the company generates modest operating cash (FY26 only ₹206 Cr, down 89% from FY25’s ₹1,880 Cr) because working capital is swollen. Inventory rose ₹66.9 Cr; receivables fell ₹72.8 Cr (mix effect from lower H2 revenue). But capex is ravenous—₹1,559 Cr outflow in FY26—leaving free cash flow deeply negative at -₹1,353 Cr. The financing side picked up ₹1,376 Cr through debt and CCD issuance to plug the gap.

This is unsustainable beyond the capex window. Once the two projects commission (expected Q2 FY27), earnings leverage to higher volumes should generate meaningful operating cash. The company’s implicit bet is that the new capacity will earn returns that justify today’s debt burden.

9 — Ratios: Sexy or Stressy?

ROCE of 11.6% is the central concern. The company is investing ₹4,650 Cr in capex at an internal rate of return that will need to exceed 11–12% to justify the debt raised. Management’s silence on post-commissioning ROCE guidance suggests either conservatism or uncertainty about volumes and spreads in a post-capex market.

10 — P&L Breakdown: Show Me the Money

Revenue has grown at a 12% trailing rate, riding volume growth in mining chemicals and fertilisers offset by pricing pressure in industrial chemicals. EBITDA peaked in FY25 (₹1,925 Cr, 18.7% margin) and contracted in FY26 despite higher revenue—a classic sign of margin compression from cost inflation, subsidy lag, and one-off shutdowns.

PAT tells the story of a business in transition. FY25 was the peak earnings year; FY26 fell 22%. The prior-year PAT benefited from a one-time tax credit; adjusting for that, underlying earnings fell ~18%, more in line with EBITDA deterioration. The trajectory suggests normalized earnings will remain under pressure until the new plants ramp and market conditions stabilize.

11 — Peer Comparison

The peer set is fragmented—no two companies are directly comparable. SRF (specialty chemicals, 42.3x P/E) is larger and more profitable; GNFC (phosphatic fertilisers, 9.0x P/E) is smaller but more efficient; Tata Chemicals is lossmaking on mining operations. Deepak sits in the middle on P/E (25.6x) but lags on ROCE (11.58% vs. peer band of 3–24%) except versus Tata Chemicals and Gujarat Alkalies. The picture: Deepak pays a premium multiple for middling returns—a bet on capex-driven improvement.

12 — Miscellaneous: Shareholding & Promoters

Promoter holding is stable at 45.6%, unchanged from prior year. The promoter structure is straightforward: Nova Synthetic (34.53%), Robust Marketing Services (8.77%), and individual family members (Deepak Chimanlal Mehta, etc.) hold the remainder. No pledging concerns—only 5.04% of shares are pledged (down from higher levels in prior years).

Management is dominated by the Mehta family. Sailesh C. Mehta is Chairman & Managing Director (and architect of the demerger strategy). The board recently appointed his son, Yeshil S. Mehta, as a non-executive director (effective July 2026) and reappointed auditor P G Bhagwat LLP for a second five-year term. No red flags here—standard family-run cyclical industrials fare, with professional governance in place.

13 — Corporate Governance: Angels or Devils?

Auditors: P G Bhagwat LLP, a mid-sized firm with 88+ years of history (in various incarnations), gave unmodified audit opinions on both standalone and consolidated results. No qualifications.

Tax matters: The company has several pending tax disputes. In AY 2015-16, a Miscellaneous Application seeking rectification of ITAT errors was dismissed (23 Feb 2026); the quantum and penalty appeals (totalling ~₹96 Cr) remain pending before the CIT(A). Management remains “confident of a favourable outcome.” This is typical for Indian chemical companies with transfer-pricing and subsidy-claim disputes; unlikely to be material if resolved.

Related-party transactions: Mahadhan AgriTech Limited (MAL, a wholly-owned subsidiary post-demerger) received significant management attention in FY26. Chairman Sailesh Mehta was appointed chairman of Deepak Mining Solutions Ltd (DMSL) effective June 2026. No spin-off or demerger timeline was disclosed, but the stated intent is to list DMSL/MAL separately to unlock value. This remains uncertain.

Credit ratings: ICRA placed DFPCL’s AA- rating on watch with negative implications (1 April 2026) due to capex/leverage concerns. The short-term A1+ rating was withdrawn. This reflects the market’s acknowledgement of balance-sheet stress during the capex cycle.

Regulatory headwinds: No major compliance failures or regulatory action. The ammonia export ban (global) and proposed self-reliance policy (India) were noted in the concall but framed as near-term, not structural.

14 — Industry Roast & Macro Context

The fertiliser industry in India is a tale of two economies. Smallholder farmers get subsidized urea and DAP at fixed retail prices; the government compensates manufacturers via NBS (nutrient-based subsidy) schemes. This system creates violent margin swings: when global input costs spike (ammonia from Russia, phosphoric acid from Middle East), manufacturers get squeezed between government price-caps and cost inflation. Elections make it worse—2026 was an Indian election year, and the government held subsidised fertiliser prices flat to appease voters, leaving companies unable to recover raw material inflation.

On the mining chemicals side, the industry benefits from India’s mining boom—coal, copper, iron ore all drive TAN demand. But supply is competitive: traditional competitors (Indian manufacturers, imports from Russia/Turkey) and now India’s own self-reliance push (the government incentivized local TAN production in recent years). Pricing is opaque but tied to global FGAN prices and local blasting costs.

The industrial chemicals side (nitric acid, IPA) is a commodity play driven by pharma, agrochemical, and electronic demand. Margins compress when feedstock (ammonia, propylene) is tight or when imports surge. China’s export bans and propylene shortages (2026) benefited Indian producers but also exposed supply-chain fragility.

Deepak Fertilisers operates in each of these arcs. The risk is clear: the company is adding capacity (mining chemicals, nitric acid) into markets that are either subsidized (fertilisers) or commodity-driven (chemicals). If demand disappoints or global supply normalizes post-capex, the new plants could underperform and drag on returns.

15 — EduInvesting Verdict

A business with everything to prove and little room for error. Deepak Fertilisers has built rare market dominance (TAN, nitric acid, speciality fertilisers), but is now doubling down with ₹4,650 Cr in new capacity at the precise moment when earnings momentum is reversing. The LNG contract and B2C mix shift are genuine structural improvements. The capex will add 1.2x current output. But returns on this capital will hinge on volume absorption, margin recovery post-subsidy lag, and commodity prices staying firm. The balance sheet can absorb one missed quarter; two would force a reckoning. A balance sheet with nothing to hide, a multiple with everything to prove.